Sector
PharmaceuticalsOpen
₹2,016.4Prev. Close
₹2,001.1Turnover(Lac.)
₹98,618.3Day's High
₹2,046.9Day's Low
₹1,965.352 Week's High
₹2,017.352 Week's Low
₹1,548Book Value
₹93.24Face Value
₹1Mkt Cap (₹ Cr.)
4,77,587.63P/E
163.06EPS
12.27Divi. Yield
0.811 Jun 2026
12:00 AM
AGM
Announcement Date: 11 Jun, 2026
10 Jul 2026
12:00 AM
Board Meeting
Agenda : Audited Result
22 May 2026
12:00 AM
Dividend
Dividend Amount: 5
Record Date: 07 Jul, 2026
10 Dec 2024
12:00 AM
EGM
AstraZeneca will continue to hold the intellectual property, manage the import licence, and retain the Marketing Authorisation for the drug.
Here are some of the stocks that may see significant price movement today: Bajaj Auto, Sterling & Wilson Renewable, Vodafone Idea, etc.
Here are some of the stocks that may see significant price movement today: Power Mech Projects, Rail Vikas Nigam, Rallis India, etc.
Here are some of the stocks that may see significant price movement today: Sun Pharma, Vedanta, SpiceJet, etc.
The visit lasted from June 2 to June 13 and focused on checking for compliance with Good Manufacturing Practices.
| Y/e 31 Mar( In .Cr) | Mar-2026 | Mar-2025 | Mar-2024 | Mar-2023 |
|---|---|---|---|---|
Equity Capital | 239.93 | 239.93 | 239.93 | 239.93 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 22,130.83 | 23,660.36 | 23,454.47 | 23,508.43 |
Net Worth | 22,370.76 | 23,900.29 | 23,694.4 | 23,748.36 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 15,585.98 | 14,116.05 | 12,531.93 | 7,923.84 |
yoy growth (%) | 10.41 | 12.64 | 58.15 | 3.12 |
Raw materials | -5,650.39 | -5,107.48 | -4,567.72 | -3,492.77 |
As % of sales | 36.25 | 36.18 | 36.44 | 44.07 |
Employee costs | -2,000.78 | -1,805.98 | -1,702.77 | -1,617.69 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 2,127.39 | 945.13 | 3,253 | 430.52 |
Depreciation | -1,349.95 | -1,236.43 | -561.56 | -432.23 |
Tax paid | -406.85 | -13.17 | -41.86 | 25.39 |
Working capital | -5,179.41 | -888.49 | 3,200.15 | 1,619.85 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 10.41 | 12.64 | 58.15 | 3.12 |
Op profit growth | 28.82 | -16.76 | 2,104.23 | 7.94 |
EBIT growth | 107.43 | -66.87 | 347.1 | 296.01 |
Net profit growth | -111.86 | -73.76 | -749.25 | 2,065.45 |
| Particulars (Rupees in Crores.) | Mar-2026 | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|---|
Gross Sales | 58,220.11 | 52,041.25 | 47,758.45 | 43,278.87 | 38,426.42 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 58,220.11 | 52,041.25 | 47,758.45 | 43,278.87 | 38,426.42 |
Other Operating Income | 241.93 | 537.19 | 738.4 | 606.81 | 228.07 |
Other Income | 1,971.72 | 1,965.04 | 1,354.19 | 634.52 | 921.51 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,990.5 | 163.06 | 4,80,046.94 | 608.7 | 0.8 | 4,887.27 | 93.23 |
Divis Laboratories Ltd DIVISLAB | 8,056 | 78.18 | 2,08,140.64 | 756 | 0.38 | 2,793 | 629.49 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 5,122.8 | 83.73 | 1,85,263.87 | 492 | 0.69 | 4,073 | 222.76 |
Cipla Ltd CIPLA | 1,473.2 | 36.12 | 1,18,430.12 | 862.16 | 0.89 | 4,672.12 | 423.36 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,126.8 | 30.15 | 1,11,271.55 | 1,722 | 0.09 | 3,564.6 | 237.3 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman / Executive Director / M D / Promoter
Dilip S Shanghvi
Executive Director & MD
Kirti Wardhaman Ganorkar
Lead Independent Non Executive Director
Pawan Goenka
Independent Non Exe. Director
Gautam Doshi
Independent Non Exe. Director
Rolf Hoffmann
ED / WTD / CFO / Promoter
AALOK DILIP SHANGHVI
E D & Wholetime Director
Vidhi Shanghvi
Independent Non Exe. Director
Satyavati Berera
Independent Non Exe. Director
Andreas Busch
Company Sec. & Compli. Officer
ANOOP ANJANIKUMAR DESHPANDE
Sun Pharma Advanced Res.Centre,
Tandalja,
Gujarat - 390020
Tel: 91-265-6615500
Website: http://www.sunpharma.com
Email: secretarial@sunpharma.com
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai-400083
Tel: 91-22-49186000
Website: https://in.mpms.mufg.com
Email: rnt.helpdesk@in.mpms.mufg.com
Summary
Sun Pharmaceutical Industries is India’s largest pharmaceutical company and among the world’s leading specialty generic drug firms, with presence in 100+ countries. Founded by Dilip Sanghvi in 1983, t...
Read More
Reports by Sun Pharmaceutical Industries Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
